Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 8/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA3 | P07451 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA6 | P23280 | 2/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1959776 | 1.00 | DNM1 (0.50) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL8811124 | 1.00 | DNM1 (0.50) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL1960836 | 1.00 | DNM1 (0.50) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL8812186 | 1.00 | DNM1 (0.50) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL381495 | 1.00 | DNM1 (0.50) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL186389 | 1.00 | — | — | |
| SCHEMBL98073 | 1.00 | — | — | |
| SCHEMBL8812602 | 1.00 | DNM1 (0.50) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL465588 | 1.00 | DNM1 (0.50) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL8812125 | 1.00 | DNM1 (0.50) | DNM1CA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 283 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11965039-B2 | Compstatin analogues and their medical uses | ZP SPV 3 K/S (DK) | 2024-04-23 | — | — | US | claimed |
| US-11851468-B2 | Treatment of neurological diseases | UNIVERSITY OF LANCASTER (GB) | 2023-12-26 | — | — | US | claimed |
| EP-4272751-A2 | COMPSTATIN ANALOGUES AND THEIR MEDICAL USES | ZP SPV 3 K/S (DK) | 2023-11-08 | — | — | EP | claimed |
| US-20230192770-A1 | COMPSTATIN ANALOGUES AND THEIR MEDICAL USES | ZEALAND PHARMA A/S (DK) | 2023-06-22 | — | — | US | claimed |
| US-11382956-B2 | Amylin analogues | ZEALAND PHARMA A/S (DK) | 2022-07-12 | — | — | US | claimed |
| EP-4021921-A1 | COMPSTATIN ANALOGUES AND THEIR MEDICAL USES | ZP SPV 3 K/S (DK) | 2022-07-06 | — | — | EP | claimed |
| CN-114630836-A | Compstatin analogs and medical uses thereof | 西兰制药第三特殊目的公司 | 2022-06-14 | — | — | CN | claimed |
| US-20220033457-A1 | TREATMENT OF NEUROLOGICAL DISEASES | UNIVERSITY OF LANCASTER (GB) | 2022-02-03 | — | — | US | claimed |
| EP-3510044-B1 | AMYLIN ANALOGUES | ZEALAND PHARMA AS (DK) | 2021-11-24 | — | — | EP | claimed |
| EP-3271381-B1 | AMYLIN ANALOGUES | ZEALAND PHARMA AS (DK) | 2021-09-08 | — | — | EP | claimed |
| US-20190134159-A1 | AMYLIN ANALOGUES | ZEALAND PHARMA A/S (DK) | 2019-05-09 | — | — | US | claimed |
| EP-3046573-B1 | AMYLIN ANALOGUES | ZEALAND PHARMA AS (DK) | 2018-12-12 | — | — | EP | claimed |
| US-10071140-B2 | Amylin analogues | ZEALAND PHARMA A/S (DK) | 2018-09-11 | — | — | US | claimed |
| WO-2018104718-A1 | TREATMENT OF NEUROLOGICAL DISEASES | LANCASTER UNIVERSITY BUSINESS ENTERPRISES LIMITED (GB) | 2018-06-14 | — | — | WO | claimed |
| US-20180071366-A1 | AMYLIN ANALOGUES | ZEALAND PHARMA A/S (DK) | 2018-03-15 | — | — | US | claimed |
| EP-3271381-A1 | AMYLIN ANALOGUES | Zealand Pharma A/S (DK) | 2018-01-24 | — | — | EP | claimed |
| WO-2016146739-A1 | AMYLIN ANALOGUES | ZEALAND PHARMA A/S (DK) | 2016-09-22 | — | — | WO | claimed |
| US-20160272693-A1 | AMYLIN ANALOGUES | ZEALAND PHARMA A/S (DK) | 2016-09-22 | — | — | US | claimed |
| EP-3046573-A2 | AMYLIN ANALOGUES | Zealand Pharma A/S (DK) | 2016-07-27 | — | — | EP | claimed |
| WO-2015040182-A2 | AMYLIN ANALOGUES | ZEALAND PHARMA A/S (DK) | 2015-03-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11965039-B2 | Compstatin analogues and their medical uses | C1QBP, C9, VIP | DNM1 2638/4885CA12 1792/4885CA1 2835/4885 |
| US-20190134159-A1 | AMYLIN ANALOGUES | IAPP, GLP1R, AMY2A | DNM1 3928/4885CA12 3493/4885CA1 4123/4885 |
| US-10071140-B2 | Amylin analogues | IAPP, GLP1R, AMY2A | DNM1 3928/4885CA12 3493/4885CA1 4123/4885 |
| US-20160272693-A1 | AMYLIN ANALOGUES | IAPP, GLP1R, AMY2A | DNM1 3928/4885CA12 3493/4885CA1 4123/4885 |
| US-20230192770-A1 | COMPSTATIN ANALOGUES AND THEIR MEDICAL USES | C1QBP, C9, VIP | DNM1 2638/4885CA12 1792/4885CA1 2835/4885 |
| US-20180071366-A1 | AMYLIN ANALOGUES | IAPP, GLP1R, AMY2A | DNM1 3928/4885CA12 3493/4885CA1 4123/4885 |
| US-11382956-B2 | Amylin analogues | IAPP, GLP1R, AMY2A | DNM1 3928/4885CA12 3493/4885CA1 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.